Business
Sareum to Present at the LSX World Congress 2021
Sareum to Present at the LSX World Congress 2021.
About this update from Sareum Holdings Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 4351N\n Sareum Holdings PLC\n 01 February 2021\n \n \n \n \n SAREUM HOLDINGS PLC\n \n \n (\"Sareum\" or \"the Company\")\n \n \n Sareum to Present at the LSX World Congress 2021\n \n \n Cambridge, UK, 1 February 2021\n - Sareum Holdings plc (AIM:SAR), the specialist small molecule drug development business, announces that its CEO, Dr Tim Mitchell, will give a Company presentation at the 7th Annual LSX World Congress, which will be delivered digitally between 1 and 5 February 2021. \n \n \n The presentation will showcase Sareum's two proprietary TYK2/JAK1 kinase inhibitor programmes, SDC-1801 and SDC-1802, targeting autoimmune diseases and cancers, respectively. Dr Mitchell will also highlight the emerging potential of this mechanism to modulate the severe inflammatory responses and respiratory symptoms arising from Covid-19 and other viral infections.\n \n \n The presentation will be made through the conference website and will be available to registered participants throughout the event - \n \n www.lsxleaders.com/lsx-world-congress\n \n \n \n \n A copy of the presentation will also be made available on Sareum's website - \n \n www.sareum.com\n \n \n \n \n For further information, please contact:\n \n \n \n \n \n Sareum Holdings plc\n \n \n Tim Mitchell, CEO\n \n \n \n \n \n \n \n \n \n \n 01223 497 700\n \n \n \n \n \n \n Strand Hanson Limited (Nominated Adviser)\n \n \n James Dance / James Bellman\n \n \n \n \n \n \n \n \n \n \n 020 7409 3494\n \n \n \n \n \n \n Hybridan LLP (Nominated Broker)\n \n \n Claire Noyce / John Beresford-Peirse\n \n \n \n \n \n \n \n \n \n \n 020 3764 2341\n \n \n \n \n \n \n Citigate Dewe Rogerson (Financial PR)\n \n \n Mark Swallow/ David Dible\n \n \n \n \n \n \n \n 020 7638 9571\n \n \n \n \n \n \n \n \n About LSX World Congress\n \n \n LSX World Congress gathers the founders and CEOs of innovative start-ups through to publicly listed life sciences giants, and everyone in between. It represents the breadth and depth of the cutting-edge research and technology driving the advances in the industry right now and in the near future.\n \n \n The industry's c-suite will be joined by the sector's most active investors, pharma and health tech BD&L teams, R&D leaders, KOLs and top tier service companies who ...